ALKERMES ($ALKS) posted quarterly earnings results on Tuesday, October 28th. The company reported earnings of $0.49 per share, beating estimates of $0.31 by $0.18. The company also reported revenue of $394,190,000, beating estimates of $363,268,308 by $30,921,692.
You can see Quiver Quantitative's $ALKS stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ALKERMES Insider Trading Activity
ALKERMES insiders have traded $ALKS stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $ALKS stock by insiders over the last 6 months:
- CRAIG C. HOPKINSON (EVP R&D, Chief Medical Officer) sold 9,000 shares for an estimated $283,776
- CHRISTIAN TODD NICHOLS (SVP, Chief Commercial Officer) has made 0 purchases and 2 sales selling 6,667 shares for an estimated $210,143.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ALKERMES Hedge Fund Activity
We have seen 176 institutional investors add shares of ALKERMES stock to their portfolio, and 189 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RTW INVESTMENTS, LP removed 2,202,409 shares (-32.0%) from their portfolio in Q2 2025, for an estimated $63,010,921
- BAKER BROS. ADVISORS LP added 1,927,318 shares (+43.0%) to their portfolio in Q2 2025, for an estimated $55,140,567
- PRICE T ROWE ASSOCIATES INC /MD/ removed 1,746,345 shares (-14.8%) from their portfolio in Q2 2025, for an estimated $49,962,930
- UBS GROUP AG removed 1,700,807 shares (-55.9%) from their portfolio in Q2 2025, for an estimated $48,660,088
- WELLINGTON MANAGEMENT GROUP LLP removed 1,396,776 shares (-45.1%) from their portfolio in Q2 2025, for an estimated $39,961,761
- PARADIGM BIOCAPITAL ADVISORS LP added 1,375,569 shares (+inf%) to their portfolio in Q2 2025, for an estimated $39,355,029
- BNP PARIBAS FINANCIAL MARKETS added 1,007,488 shares (+787.2%) to their portfolio in Q2 2025, for an estimated $28,824,231
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ALKERMES Analyst Ratings
Wall Street analysts have issued reports on $ALKS in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Mizuho issued a "Outperform" rating on 10/27/2025
- Piper Sandler issued a "Overweight" rating on 10/23/2025
- RBC Capital issued a "Outperform" rating on 09/26/2025
- Needham issued a "Buy" rating on 07/29/2025
- Goldman Sachs issued a "Buy" rating on 07/15/2025
- UBS issued a "Buy" rating on 06/17/2025
- Baird issued a "Outperform" rating on 05/02/2025
To track analyst ratings and price targets for ALKERMES, check out Quiver Quantitative's $ALKS forecast page.
ALKERMES Price Targets
Multiple analysts have issued price targets for $ALKS recently. We have seen 10 analysts offer price targets for $ALKS in the last 6 months, with a median target of $44.5.
Here are some recent targets:
- Uy Ear from Mizuho set a target price of $45.0 on 10/27/2025
- Leonid Timashev from RBC Capital set a target price of $47.0 on 10/23/2025
- David Amsellem from Piper Sandler set a target price of $45.0 on 10/23/2025
- Douglas Tsao from HC Wainwright & Co. set a target price of $46.0 on 09/09/2025
- Jessica Fye from JP Morgan set a target price of $35.0 on 09/09/2025
- Benjamin Burnett from Wells Fargo set a target price of $44.0 on 09/03/2025
- Ami Fadia from Needham set a target price of $45.0 on 07/29/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
